Advaxis, Inc. (NASDAQ:ADXS) most recently reported quarterly actual earnings per share of $-0.48 for the period ending on 2016-07-31. Prior to the company reporting, consensus estimates based on data from Zacks Research projected the company to report EPS of $-0.22. The difference between the estimate and the actual EPS was $-0.26 creating a surprise factor of -118.18%. Currently, the company has an impact score of 0. The likelihood that the stock will move on news is greater with a higher impact score. According to Beta Research, the stock has a sentiment score of -0.044. On a scale between 1 and -1, a positive score tends to portray a favorable view of company results by news outlets. The opposite is true for a negative sentiment score.

In taking a look at where the stock might be headed, analysts have a consensus price target of $23.6 on the shares. The most bullish brokerage firm has a $26 target, while the most bearish sees the stock headed towards $20. This is according to the 5 estimates taken into consideration by Zacks Research.

In terms of Buy/Sell recommendations, analysts have a consensus rating of 1. This is according to a simplified scale where 1 represents a Strong Buy and 5 a Strong Sell recommendation. There were 5 recommendations taking into account in order to arrive at this number. Of the 5, 5 have a Strong Buy rating and 0 are rating it a Buy.

Advaxis, Inc. is a clinical development-stage company. The Company is a biotechnology company with the focus to develop safe and effective immunotherapies for cancer and infectious diseases. These immunotherapies are based on a platform technology under license from the University of Pennsylvania (Penn), that utilizes live attenuated Listeria monocytogenes (Lm), bioengineered to secrete antigen/adjuvant fusion proteins. These Lm strains use a fragment of the protein listeriolysin (LLO), fused to a tumor associated antigen (TAA) or other antigen of interest. In addition, the Company has developed immunotherapies for prostate cancer and HER2 overexpressing cancers (such as breast, gastric and other cancers in humans and for osteosarcoma in canines).

Advaxis, Inc. - Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with’s FREE daily email newsletter.